MR. ALFONSO CUTUGNO, MD

RHINEBECK, NY

Research Active
Internal Medicine - Medical Oncology NPI registered 21+ years 1 publication 2014 – 2014 NPI: 1477555761
Internal Medicine - Medical Oncology Internal Medicine - Hematology & Oncology

Practice Location

6511 SPRING BROOK AVE STE 101
RHINEBECK, NY 12572-3709

Phone: (845) 871-3545

What does ALFONSO CUTUGNO research?

Dr. Cutugno researches complex cancers, especially those that involve tumors with unclear origins, such as certain lung cancers. He examines how genetic changes, like the EML4-ALK rearrangement, can be targeted with specific medications, such as crizotinib. His findings demonstrate how understanding a tumor's genetic makeup can lead to more effective treatment options for patients who might be facing difficult-to-treat cancers.

Key findings

  • A patient with a poorly differentiated malignancy and an EML4-ALK genetic change responded positively to crizotinib, showing significant improvement in both lung and arm tumors.
  • The study emphasizes that advanced genetic testing can clarify confusing cancer diagnoses, leading to tailored therapies.
  • Targeted therapy with crizotinib resulted in a notable reduction of tumor size and symptoms for the patient.

Frequently asked questions

Does Dr. Cutugno study cancer?
Yes, he specializes in researching complex cancers, particularly those with unclear origins.
What treatments has Dr. Cutugno researched?
He has researched targeted therapy using crizotinib for patients with specific genetic changes in their tumors.
Is Dr. Cutugno's work relevant to patients with unclear cancer diagnoses?
Yes, his research focuses on how genetic testing can lead to better treatment options for patients whose tumors are difficult to identify.

Publications in plain English

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib.

2014

Case reports in oncology

Chung JH, Ali SM, Davis J, Robstad K, McNally R +7 more

Plain English
This study focused on a patient with tumors in the lungs and an unclear tumor in the arm. Despite challenges in determining where the arm tumor came from, advanced genetic testing revealed a specific genetic change known as EML4-ALK. The patient responded well to a targeted drug called crizotinib, showing significant improvement in both tumors. This matters because it highlights the importance of genetic testing in diagnosing and treating hard-to-identify cancers, leading to more effective therapies. Who this helps: This helps cancer patients with unclear tumor origins and their doctors.

PubMed

Frequent Co-Authors

Jon H Chung Siraj M Ali Jenni Davis Karl Robstad Richard McNally Laurie M Gay Rachel L Erlich Norma A Palma Phil J Stephens Vincent A Miller

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.